Society Statements

Position Statements

At the Endocrine Society, we are concerned about a number of critical policy issues. Our goals are to ensure that the full body of research available is available to policy makers and to affect positive change by advocating for increased research and updated regulatory processes.

  • Central Institutional Review Boards | April 2016
    Clinical research involving human participants is critical to develop treatments for a broad spectrum of diseases, including many endocrine disorders lacking specialized treatments…
  • Research Funding | April 2016
    A half century of sustained investment by the United States Federal Government in biomedical research has dramatically advanced the health and improved the lives of the American people…
  • Affordable Care Act Implementation Challenges and Opportunities to Impact Patients With Diabetes | January 2016
    In the United States, slightly more than half of all adults with diabetes receive guideline-consistent care. A smaller proportion has adequate cardiovascular risk…
  • Endocrine-Disrupting Chemicals in the European Union | June 2015
    The European Union (EU) has introduced specific legislative obligations aimed at phasing out endocrine disruptors in water, industrial chemicals, plant protection products and biocides. The European Commission…
  • Pediatric Obesity | November 2011
    Pediatric obesity in the United States is an epidemic. Although obesity rates vary among different ethnic groups, an estimated 17% (12.5 million) of US children ages 2-19 years are overweight or obese…
  • Endocrine-Disrupting Chemicals | June 2009
    Endocrine disrupting chemicals (EDCs) are broadly defined as chemicals that can interfere with hormone action. These chemicals are designed, produced, and marketed…
  • Stem Cell Research | October 2009
    Stem cell research holds great promise for the treatment of the millions of Americans with debilitating and possibly fatal diseases including diabetes, heart disease, Parkinson’s disease, Alzheimer’s disease…
  • Medicare Coverage of DXA Bone Density Testing in Men | June 2009
    Hypogonadism in men is a condition in which the body does not produce enough of the male sex hormone testosterone. Testosterone deficiency affects 4-5 million men in the United States and places these individuals at risk for developing osteoporosis.…
  • Bioequivalence of Sodium Levothyroxine | June 2008
    The Endocrine Society is concerned that patients are frequently being placed at risk by the undisclosed substitution of sodium levothyroxine (L-T4), a prescription medication used for the treatment of thyroid disease…
  • Steroid Abuse | June 2008
    While anabolic steroids clearly serve an important clinical need, they also are increasingly abused by athletes seeking to enhance physical performance and by others seeking to enhance physical appearance…
  • Access to Affordable and Adequate Diabetes Supplies | October 2007
    Diabetes is a life-threatening disease affecting more than 20 million Americans. Individuals with diabetes must manage and treat their condition on a daily basis with the guidance of physicians…
  • Bioidentical Hormones | October 2006
    “Bioidentical hormones,” particularly estrogen and progesterone, have been promoted as safer and more effective alternatives to more traditional hormone therapies, often by people outside…
  • Clinical Trial Registries | June 2006
    In response to the growing public concern about the timely and complete reporting of clinical trials results and recent policy statements of the The International Conference of Medical Journal Editors…

Additional Society Statements

See all additional statements